Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Benserazide | hsa00020 | Citrate cycle (TCA cycle) | 2.78E-02 | 2 | O75390, P40926 | CS, MDH2 | More | | Benserazide | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Benserazide | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Benserazide | hsa03013 | RNA transport | 2.53E-02 | 6 | P62826, Q15287, Q9UBU9, P63279, Q13310, P20042 | RAN, RNPS1, NXF1, UBE2I, PABPC4, EIF2S2 | More | | Benserazide | hsa03015 | mRNA surveillance pathway | 4.25E-02 | 4 | Q13310, Q13362, Q15287, Q9UBU9 | PABPC4, PPP2R5C, RNPS1, NXF1 | More | | Benserazide | hsa04020 | Calcium signaling pathway | 4.11E-03 | 6 | Q96DU7, Q08828, Q13557, P61073, P05141, P51828 | ITPKC, ADCY1, CAMK2D, CXCR4, SLC25A5, ADCY7 | More | | Benserazide | hsa04114 | Oocyte meiosis | 2.64E-02 | 5 | Q13557, Q08828, P51828, P27348, Q13362 | CAMK2D, ADCY1, ADCY7, YWHAQ, PPP2R5C | More | | Benserazide | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.32E-02 | 5 | Q08828, P51828, P18848, Q13362, Q13557 | ADCY1, ADCY7, ATF4, PPP2R5C, CAMK2D | More | | Benserazide | hsa04650 | Natural killer cell mediated cytotoxicity | 4.40E-02 | 6 | P78314, P06239, O60880, P20963, P26718, O75015 | SH3BP2, LCK, SH2D1A, CD247, KLRK1, FCGR3B | More | | Benserazide | hsa04658 | Th1 and Th2 cell differentiation | 9.73E-03 | 6 | P20963, P09693, Q16539, P06239, Q9UL17, P13765 | CD247, CD3G, MAPK14, LCK, TBX21, HLA-DOB | More | | Benserazide | hsa04659 | Th17 cell differentiation | 7.42E-03 | 7 | Q16539, P06239, P13765, P14778, Q9UL17, P09693, P20963 | MAPK14, LCK, HLA-DOB, IL1R1, TBX21, CD3G, CD247 | More | | Benserazide | hsa04725 | Cholinergic synapse | 2.45E-02 | 4 | Q08828, P51828, P18848, Q13557 | ADCY1, ADCY7, ATF4, CAMK2D | More | | Benserazide | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.77E-02 | 4 | P01584, Q08828, P51828, Q13557 | IL1B, ADCY1, ADCY7, CAMK2D | More | | Benserazide | hsa04911 | Insulin secretion | 4.73E-03 | 4 | Q08828, P51828, P18848, Q13557 | ADCY1, ADCY7, ATF4, CAMK2D | More | | Benserazide | hsa04912 | GnRH signaling pathway | 2.45E-02 | 4 | Q08828, P51828, P18848, Q13557 | ADCY1, ADCY7, ATF4, CAMK2D | More | | Benserazide | hsa04916 | Melanogenesis | 3.73E-02 | 3 | Q13557, Q08828, P51828 | CAMK2D, ADCY1, ADCY7 | More | | Benserazide | hsa04925 | Aldosterone synthesis and secretion | 1.77E-02 | 4 | P18848, Q08828, P51828, Q13557 | ATF4, ADCY1, ADCY7, CAMK2D | More | | Benserazide | hsa04927 | Cortisol synthesis and secretion | 2.51E-02 | 3 | P18848, Q08828, P51828 | ATF4, ADCY1, ADCY7 | More | | Benserazide | hsa04932 | Non-alcoholic fatty liver disease | 2.07E-02 | 5 | P18848, O75460, P01584, P12074, O15239 | ATF4, ERN1, IL1B, COX6A1, NDUFA1 | More | | Benserazide | hsa04934 | Cushing syndrome | 1.22E-02 | 4 | P18848, Q08828, P51828, Q13557 | ATF4, ADCY1, ADCY7, CAMK2D | More | | Benserazide | hsa04971 | Gastric acid secretion | 4.73E-03 | 4 | Q08828, P51828, P15311, Q13557 | ADCY1, ADCY7, VIL2, CAMK2D | More | | Benserazide | hsa05010 | Alzheimer disease | 1.50E-02 | 9 | O15239, P05496, P12074, Q00535, O75460, P01584, P18848, P05141, P28070 | NDUFA1, ATP5G1, COX6A1, CDK5, ERN1, IL1B, ATF4, SLC25A5, PSMB4 | More | | Benserazide | hsa05012 | Parkinson disease | 1.20E-02 | 8 | O15239, P12074, P05496, P05141, O75460, P18848, P28070, Q13557 | NDUFA1, COX6A1, ATP5G1, SLC25A5, ERN1, ATF4, PSMB4, CAMK2D | More | | Benserazide | hsa05016 | Huntington disease | 1.72E-02 | 8 | O15239, P12074, P05496, P30876, P62487, P05141, O75460, P28070 | NDUFA1, COX6A1, ATP5G1, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4 | More | | Benserazide | hsa05020 | Prion disease | 3.72E-02 | 8 | P01584, P46531, O15239, P05496, P12074, P18848, P05141, P28070 | IL1B, NOTCH1, NDUFA1, ATP5G1, COX6A1, ATF4, SLC25A5, PSMB4 | More | | Benserazide | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.74E-02 | 10 | O15239, P12074, P05496, O75460, P18848, P05141, Q00535, P01584, Q13557, P28070 | NDUFA1, COX6A1, ATP5G1, ERN1, ATF4, SLC25A5, CDK5, IL1B, CAMK2D, PSMB4 | More | | Benserazide | hsa05144 | Malaria | 1.44E-02 | 4 | P60033, O60603, P35443, P26718 | CD81, TLR2, THBS4, KLRK1 | More | | Benserazide | hsa05163 | Human cytomegalovirus infection | 2.74E-02 | 7 | Q08828, P51828, P23458, P01584, P61073, Q13651, P18848 | ADCY1, ADCY7, JAK1, IL1B, CXCR4, IL10RA, ATF4 | More | | Benserazide | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Benserazide | hsa05203 | Viral carcinogenesis | 3.32E-02 | 5 | P18848, P23458, P27348, Q7KZF4, P61978 | ATF4, JAK1, YWHAQ, SND1, HNRPK | More | | Benserazide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.03E-02 | 5 | P20963, P09693, P06239, O60603, Q16539 | CD247, CD3G, LCK, TLR2, MAPK14 | More | | |